The broad markets are continuing to hit all-time highs as the market is shifting gears out of the earnings season. Despite all the positive sentiment in the market, quite a few companies still struggled. Even though the market made incredible gains, a few companies held it back from pushing even higher.

24/7 Wall Street has picked out a few companies posting some of the largest losses for the week. Companies hitting lows and creating huge shareholder hits when the market is hitting all-time highs are not exactly winning the hearts and minds of the investing community.

We have included a note on why the stock has lagged, as well as a recent trading history, consensus analyst price target and a 52-week trading range.

Myriad Genetics

On Tuesday, Myriad Genetics Inc. (NASDAQ: MYGN) reported its fiscal fourth-quarter results and shares promptly tanked. The company said that it had $0.36 in earnings per share (EPS) on $186.5 million in revenue. These were under estimates by about $2 million in sales and six cents on earnings.

Myriad’s miss was almost entirely attributable to lower than expected myRisk Hereditary Cancer Testing sales, which was due to pricing pressure and market share loss. The big part of the disappointment here is that the 2017 sales and earnings guidance were roughly 11% and 30%, respectively, short of consensus expectations. Gross margin declined 170 basis points (still at 78.5%) and operating margin was down about 400 basis points to 19%.

Over the past week, the stock dropped by 29%. Shares were trading at $21.54 on Friday’s close, with a consensus price target of $23.90 and a 52-week trading range of $19.10 to $46.24.

SunPower

After markets closed Tuesday, SunPower Corp. (NASDAQ: SPWR) reported its second-quarter 2016 results. The solar panel maker reported an adjusted diluted net loss of $0.22 per share on adjusted revenue of $401.8 million. In the same period a year ago, SunPower reported earnings per share (EPS) of $0.18 on revenue of $376.71 million.

Second-quarter results also compare to the Thomson Reuters consensus estimates for a net loss per share of $0.24 and $345.08 million in revenue. The big news from SunPower on Tuesday was a restructuring that will include a workforce reduction of about 1,200 employees and charges totaling $30 million to $45 million.

The company said a “substantial” portion of the charges will be incurred in the third quarter and more than half the charges will be in cash. Operating expenses are expected to drop by about 10% following the layoffs.

Despite some big downgrades, a few analysts still see SunPower shining brightly.

Over the past week, SunPower shares dropped by 31%. The stock closed trading at $10.85 on Friday, with a consensus price target of $19.61 and a 52-week range of $10.05 to $31.10.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Cliffs Natural Resources

Cliffs Natural Resources (NYSE: CLF) announced the pricing of its secondary underwritten offering early last week. The company agreed to sell approximately 44.4 million common shares at a public offering price of $6.75 per share. This values the offering at nearly $300 million.

Cliffs Natural Resources showed in filings that the company’s use of proceeds will be used for general corporate purposes. The company noted in the details that this use will include the repayment of debt, in particular its senior notes due January 2018.

Cliffs’ shares dropped by 21% last week, closing the week at $6.35, with a consensus price target of $6.50 and a 52-week range of $1.20 to $8.45.

Impax Laboratories

When Impax Laboratories Inc. (NASDAQ: IPXL) reported its second-quarter financial results on Tuesday, the company said it had $0.21 in EPS on $172.6 million in revenue. The consensus estimates were $0.33 in EPS on $233.6 million in revenue. Ultimately management said these weaker results reflected the unexpected and rapid decline in sales of diclofenac and metaxalone as a result of additional competition.

Fred Wilkinson, president and chief executive of Impax, further detailed:

In particular, the change in the diclofenac market quickly moved us from an exclusive supplier position to a five competitor market. Unfortunately, the swiftness of the change in both of these product markets combined with lower sales of mixed amphetamine salts, more than offset solid growth from our epinephrine auto-injector and oxymorphone products, as well as growth in sales across our Specialty Pharma portfolio.

Over the past week, the stock dropped by 30%. Shares were trading at $21.72 on Friday’s close, with a consensus price target of $30.57 and a 52-week range of $20.98 to $47.48.

Array BioPharma and AstraZeneca

Array BioPharma Inc. (NASDAQ: ARRY) watched its shares suffer when AstraZeneca PLC (NYSE: AZN) announced results from its Phase 3 SELECT-1 trial of selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive locally advanced or metastatic non-small cell lung cancer.

Ultimately, these results showed that the trial did not meet its primary endpoint of progression-free survival, and selumetinib did not have a significant effect on overall survival (OS).

This failure is pertinent to Array because AstraZeneca acquired exclusive worldwide rights to selumetinib from Array. To date, Array received $26.5 million in upfront and milestone payments and is entitled to potential additional development milestone payments of approximately $70 million (with $30 million specific for selumetinib) and royalties on product sales. So this late-stage failure does not help Array in the least bit.

Over the past week, Array shares retreated 23.5%. They were last trading at $3.53. The consensus price target is $7.83, and the 52-week range is $2.38 to $6.04.

AstraZeneca didn’t see its shares affected that severely from the announcement, with the stock only down 2.5% on the week. The stock closed at $33.54 on Friday. The consensus price target is $34.50, and the 52-week trading range is $26.97 to $35.04.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.